Mereo BioPharma Group (MREO) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 62.7% versus a loss of 80.9%. Zhengye Biotechnology is the larger company by market cap ($82.0 million vs $55.9 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MREO | ZYBT |
|---|---|---|
| Share price | $0.3499 | $1.73 |
| Market cap | $55.88M | $81.99M |
| 1-day change | -6.74% | +50.45% |
| YTD return | -10.02% | -0.01% |
| 1-year return | -80.86% | -62.67% |
| 5-year return | -82.79% | — |
| EPS (TTM) | $-0.20 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.37 | $8.01 |
| 52-week low | $0.20 | $0.616 |
| Distance from 52-week high | -85.24% | -78.40% |
| Analyst consensus | none | — |
| Avg. price target upside | +460.16% | — |
| Average volume | 4.04M | 5.10M |
| Shares outstanding | 159.69M | 47.39M |
| Employees | 39 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed MREO by 18.2 percentage points over the past year.
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
MREO vs ZYBT FAQ
Which is bigger, Mereo BioPharma Group or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $81.99M compared with $55.88M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, MREO or ZYBT?
ZYBT returned -62.67% over the past 12 months, compared with -80.86% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Mereo BioPharma Group and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.